No­var­tis' big PD-1 bet turns sour; $350M res­ur­rec­tion sto­ry; Con­tra­cep­tive for men heads to clin­ic; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.